New treatment approved by NICE for advanced soft tissue sarcoma
30 August 2017 - New treatment approved by NICE for advanced soft tissue sarcoma
The approval of a new treatment for sarcoma by the National Institute for Health and Care Excellence (NICE) has been hailed as a “major breakthrough” by the cancer charity Sarcoma UK, which played a leading role in the effort to have the drug approved. https://sarcoma.org.uk/Ola
Following on from the publication of exciting data from a phase 2 trial last year, NICE has approved the use of olaratumab (also known as Lartruvo™) in combination with doxorubicin for advanced soft tissue sarcoma in the first-line setting. Doxorubicin has been the backbone of first line chemotherapy for soft tissue sarcoma for over 30 years and the early data suggests that olaratumab may have significant benefit in terms of overall survival.
Olaratumab is the first new treatment since 2010 to be approved by NICE for advanced soft tissue sarcoma and it has been approved within the NHS in England until 2020. During this time, further data will be collected, including from a Phase 3 clinical trial and at the end of this period, it will be re-assessed.
For further information about olaratumab, please consult your clinician, download Sarcoma UK’s fact sheet or call the Sarcoma UK Support Line on 0808 801 0401.